Theranexus SA logo

ALTHX - Theranexus SA News Story

€3.18 -0.0  -0.6%

Last Trade - 2:35pm

Sector
Healthcare
Size
Micro Cap
Market Cap £12.2m
Enterprise Value £5.63m
Revenue £n/a
Position in Universe 746th / 849

BRIEF-Theranexus H1 Net Operating Loss Widens To 4.6 Million Euros

Thu 30th September, 2021 5:27pm
Sept 30 (Reuters) - Theranexus SA  ALTHX.PA :
    * H1 NET LOSSES WERE -€3,723 K , COMPARED WITH -€2,870 K IN
THE
FIRST HALF OF 2020
    * TOTAL AVAILABLE FUNDS ON 30 JUNE 2021 STOOD AT €13.5 M,
COMPARED
WITH €11.2 M ON 31 DECEMBER 2020
    * COMPANY'S CASH POSITION IS RELATIVELY STABLE AND PROVIDES
FINANCIAL VISIBILITY FOR THE NEXT 18 MONTHS IN ACCORDANCE WITH
ITS SET TARGETS
    * DRUG CANDIDATE BBDF 101 FOR BATTEN DISEASE: CLINICAL
PROGRAM
WILL START BY THE END OF 2021 WITH PHASE I/II. PHASE III WILL
START AFTER CONSULTING WITH THE FDA IN THE SECOND HALF OF 2022
    * H1 NET OPERATING LOSS EUR 4.6 MILLION VERSUS LOSS EUR 3.4
MILLION YEAR AGO

Source text for Eikon:  ID:nNDL6nBFWf 
Further company coverage:  ALTHX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;))
© Stockopedia 2022, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.